Solid pharmaceutical dosage form

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least o...

Full description

Saved in:
Bibliographic Details
Main Authors Rosenberg, Joerg, Reinhold, Ulrich, Liepold, Bernd, Berndl, Gunther, Breitenbach, Joerg, Alani, Laman, Ghosh, Soumojeet
Format Patent
LanguageEnglish
Published 18.12.2012
Online AccessGet full text

Cover

More Information
Summary:A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.